WASHINGTON (February 22, 2013)—The U.S. Food and Drug Administration has approved a new form of the best-selling breast cancer drug Kadcyla, which targets tumor cells while sparing healthy ones.
The drug from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together.
The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.
The FDA approved the drug for about 20 percent of breast cancer patients who have a particular form of the disease involving tumors that overproduce the protein HER-2.
The approval will help Roche build on the success of Herceptin, which has long dominated the breast cancer marketplace.
The drug had sales of $6 billion last year.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.